Here's How Trump's Pick To Lead The FDA Can Supercharge The Agency
The U.S. Senate last week confirmed former Johns Hopkins surgeon and professor Dr. Marty Makary to lead the Food and Drug ...
Fierce Pharma1d
FDA staff cuts could disrupt drug reviews, putting agency's critical funding programs at risk: reports
Massive cuts at the FDA have hit staff tied to drug reviews and user fees, putting future approvals in jeopardy, according to multiple reports.
FDA delays full approval of Novavax COVID-19 vaccine even though it was on track for clearance
The FDA has delayed granting full approval of Novavax's COVID-19 vaccine despite it being on track to be cleared until ...
CNN2d
FDA delays full approval of Novavax Covid-19 vaccine even though it was on track for clearance
The US Food and Drug Administration has delayed granting full approval of Novavax ... A spokesman for HHS told CNN, “The FDA’s independent review process for the Novavax vaccine, like ...
HealthDay on MSN1d
FDA Delays Final Approval of Novavax COVID Vaccine
Key Takeaways The U.S. Food and Drug Administration has delayed full approval of Novavax's COVID vaccineThe agency says it needs more data before making a final decisionNovavax says its vaccine is ...
Why Biotech Stocks Like Recursion Pharmaceuticals, CRISPR Therapeutics, and Summit Therapeutics Plunged Today
Recursion Pharmaceuticals uses artificial intelligence (AI) in its proprietary operating system to match new compounds ...
Axios on MSN2d
Drug industry worries about FDA delays
Pharmaceutical companies are growing increasingly concerned widespread cuts at the Food and Drug Administration could set the ...
Opinion
Comment: Drug companies need to speak up about RFK Jr.’s FDA
Over the last two months, the pharmaceutical industry has remained on the sidelines as Health and Human Services Secretary Robert F. Kennedy Jr. and Elon Musk’s Department of Government Efficiency ...
The Harvard Crimson1d
FDA Layoffs, Funding Cuts Cast Shadow Over Biopharma Industry
Amid a raft of federal changes cutting funding and capacities at the Food and Drug Administration, investors are soon ...
Fierce Pharma2d
For struggling cell and gene therapy field, Peter Marks' FDA exit adds even more uncertainty
The sudden resignation of Peter Marks, M.D., Ph.D., from the FDA branch that regulates biological products for humans ...